Nonalcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER
You are invited to participate in a research study that seeks to understand the effect of non-alcoholic fatty liver disease (NAFLD) on organs other than the liver. One of the most common organs affected in patients with NAFLD is the heart. We expect to have about 88 people participate in this study at University of California (UC), Davis. About three-fourths (66) of the participants will be patients who have been diagnosed with NAFLD. The other one-fourth (22) will be healthy individuals with no known liver disease. These healthy subjects will allow researchers to compare healthy organs or body functions with those of persons with NAFLD. The healthy participants are called the "Healthy Control" group. All participants will undergo the same testing. If you agree to participate in this study, researchers will first interview you and review your medical records in order to document your medical (clinical) history. You will also have a physical examination by a doctor and a blood test. You will then undergo a series of imaging tests to determine the status of your liver, heart and other internal organs. All participants will have a PET/CT Scan (Positron Emission Tomography), and an MRI (Magnetic Resonance Imaging). All participants will also have an Electrocardiogram and an Echocardiogram. All Electrocardiogram tests are the same, but there are two types of Echocardiogram tests. One is like a standard ultra-sound imaging of your heart. The other is a "Stress Cardio" that will require you to increase your heart rate on a treadmill before the ultra-sound test. Your study doctor will determine which test you have. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04880031 -
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Suspended |
NCT04104321 -
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
|
Phase 3 | |
| Completed |
NCT02891408 -
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT04546984 -
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
|
Phase 1 | |
| Recruiting |
NCT05842512 -
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
|
Phase 2 | |
| Completed |
NCT02854605 -
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT06108219 -
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
|
Phase 2 | |
| Recruiting |
NCT03572465 -
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
|
||
| Active, not recruiting |
NCT05402371 -
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
|
Phase 2 | |
| Terminated |
NCT03823703 -
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT05117489 -
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
| Recruiting |
NCT04913090 -
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06024408 -
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
|
Phase 1 | |
| Terminated |
NCT04004325 -
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
| Completed |
NCT06037577 -
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05320146 -
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
||
| Completed |
NCT01265498 -
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
|
Phase 2 | |
| Terminated |
NCT00845845 -
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Terminated |
NCT04267393 -
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT04616014 -
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 |